These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
588 related articles for article (PubMed ID: 24130769)
1. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, enhances radiosensitivity and suppresses lung metastasis in breast cancer in vitro and in vivo. Chiu HW; Yeh YL; Wang YC; Huang WJ; Chen YA; Chiou YS; Ho SY; Lin P; Wang YJ PLoS One; 2013; 8(10):e76340. PubMed ID: 24130769 [TBL] [Abstract][Full Text] [Related]
2. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model. Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975 [TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells. Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415 [TBL] [Abstract][Full Text] [Related]
4. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts. Baschnagel A; Russo A; Burgan WE; Carter D; Beam K; Palmieri D; Steeg PS; Tofilon P; Camphausen K Mol Cancer Ther; 2009 Jun; 8(6):1589-95. PubMed ID: 19509253 [TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid (Zolinza/vorinostat) sensitizes TRAIL-resistant breast cancer cells orthotopically implanted in BALB/c nude mice. Shankar S; Davis R; Singh KP; Kurzrock R; Ross DD; Srivastava RK Mol Cancer Ther; 2009 Jun; 8(6):1596-605. PubMed ID: 19509267 [TBL] [Abstract][Full Text] [Related]
6. Combination of rapamycin and SAHA enhanced radiosensitization by inducing autophagy and acetylation in NSCLC. Wang Y; Liu F; Fang C; Xu L; Chen L; Xu Z; Chen J; Peng W; Fu B; Li Y Aging (Albany NY); 2021 Jul; 13(14):18223-18237. PubMed ID: 34321364 [TBL] [Abstract][Full Text] [Related]
7. Combined Effects of Suberoylanilide Hydroxamic Acid and Cisplatin on Radiation Sensitivity and Cancer Cell Invasion in Non-Small Cell Lung Cancer. Feng J; Zhang S; Wu K; Wang B; Wong JY; Jiang H; Xu R; Ying L; Huang H; Zheng X; Chen X; Ma S Mol Cancer Ther; 2016 May; 15(5):842-53. PubMed ID: 26839308 [TBL] [Abstract][Full Text] [Related]
8. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells. You BR; Han BR; Park WH Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148 [TBL] [Abstract][Full Text] [Related]
9. Pracinostat (SB939), a histone deacetylase inhibitor, suppresses breast cancer metastasis and growth by inactivating the IL-6/STAT3 signalling pathways. Chen J; Li N; Liu B; Ling J; Yang W; Pang X; Li T Life Sci; 2020 May; 248():117469. PubMed ID: 32109485 [TBL] [Abstract][Full Text] [Related]
10. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells. Marijon H; Lee DH; Ding L; Sun H; Gery S; de Gramont A; Koeffler HP Biomed Pharmacother; 2018 Mar; 99():543-551. PubMed ID: 29902865 [TBL] [Abstract][Full Text] [Related]
11. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer. Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446 [TBL] [Abstract][Full Text] [Related]
12. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Palmieri D; Lockman PR; Thomas FC; Hua E; Herring J; Hargrave E; Johnson M; Flores N; Qian Y; Vega-Valle E; Taskar KS; Rudraraju V; Mittapalli RK; Gaasch JA; Bohn KA; Thorsheim HR; Liewehr DJ; Davis S; Reilly JF; Walker R; Bronder JL; Feigenbaum L; Steinberg SM; Camphausen K; Meltzer PS; Richon VM; Smith QR; Steeg PS Clin Cancer Res; 2009 Oct; 15(19):6148-57. PubMed ID: 19789319 [TBL] [Abstract][Full Text] [Related]
13. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines. Feng X; Han H; Zou D; Zhou J; Zhou W Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517 [TBL] [Abstract][Full Text] [Related]
14. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators. Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497 [TBL] [Abstract][Full Text] [Related]
15. Crosstalk between lysine-specific demethylase 1 (LSD1) and histone deacetylases mediates antineoplastic efficacy of HDAC inhibitors in human breast cancer cells. Vasilatos SN; Katz TA; Oesterreich S; Wan Y; Davidson NE; Huang Y Carcinogenesis; 2013 Jun; 34(6):1196-207. PubMed ID: 23354309 [TBL] [Abstract][Full Text] [Related]
16. Synergistic effects of combined treatment with histone deacetylase inhibitor suberoylanilide hydroxamic acid and TRAIL on human breast cancer cells. Zhou W; Feng X; Han Han ; Guo S; Wang G Sci Rep; 2016 Jun; 6():28004. PubMed ID: 27292433 [TBL] [Abstract][Full Text] [Related]
17. Novel Suberoylanilide Hydroxamic Acid Analogs Inhibit Angiogenesis and Induce Apoptosis in Breast Cancer Cells. Moku G; Vangala S; Yakati V; Gali CC; Saha S; Madamsetty VS; Vyas A Anticancer Agents Med Chem; 2022; 22(5):914-925. PubMed ID: 34488592 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells. Lee YJ; Won AJ; Lee J; Jung JH; Yoon S; Lee BM; Kim HS Int J Med Sci; 2012; 9(10):881-93. PubMed ID: 23155362 [TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces growth inhibition and enhances taxol-induced cell death in breast cancer. Shi YK; Li ZH; Han XQ; Yi JH; Wang ZH; Hou JL; Feng CR; Fang QH; Wang HH; Zhang PF; Wang FS; Shen J; Wang P Cancer Chemother Pharmacol; 2010 Nov; 66(6):1131-40. PubMed ID: 20838997 [TBL] [Abstract][Full Text] [Related]
20. Antitumor action of a novel histone deacetylase inhibitor, YF479, in breast cancer. Zhang T; Chen Y; Li J; Yang F; Wu H; Dai F; Hu M; Lu X; Peng Y; Liu M; Zhao Y; Yi Z Neoplasia; 2014 Aug; 16(8):665-77. PubMed ID: 25220594 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]